In the field of innovative drug discovery, efficiently screening lead molecules with covalent binding activity from complex natural products has long been a technical challenge. A recent study published in iMeta has successfully developed a clickable probe-based protein chip platform (Ccc-Chip), enabling high-throughput screening of 110 medicinal plant extracts. From this screen, the novel covalent mIDH1 inhibitor Flavokawain C (Flc) was identified, offering a new paradigm for targeted therapy against refractory tumors.
Core Breakthrough: Ccc-Chip Platform Enables Precise Targeting of Active Molecules in Natural Products
Traditional covalent drug screening methods (e.g., LC-ESI-MS) often suffer from low throughput and cumbersome procedures when dealing with complex natural product extracts. This study innovatively combines bio-orthogonal click chemistry with protein chip technology to construct the Ccc-Chip platform. By employing competitive binding between the cysteine-targeting probe IAA-yne and target proteins, the platform allows intuitive and efficient assessment of whether components in natural extracts possess covalent binding capacity.
Key Technical Approach:
Integrated screening strategy: A two-step approach combining DSF pre-screening with Ccc-Chip core validation ensures both screening throughput and result accuracy.
High-throughput validation: Systematic screening of 110 medicinal plant extracts, coupled with preparative liquid chromatography and mass spectrometry, ultimately pinpointed the active ingredient Flc from Piper methysticum Forst. (kava).
In-depth mechanistic dissection: Techniques including MALDI-TOF/TOF, LC-MS/MS, and BLI confirmed that Flc selectively inhibits mutant IDH1 activity via covalent binding to the Cys269 residue, with a Kd of 0.516 μM for IDH1-R132H.
Hard Data: Multi-dimensional Validation from Molecular Mechanism to In Vivo Efficacy
This study not only elucidates the mechanism of Flc at the molecular level but also demonstrates its anti-tumor and immunomodulatory activities in multiple animal models.
Precise targeting: Flc exhibits 8–9-fold higher affinity for mutant IDH1 (R132H/R132C) compared to the wild-type, with no significant cytotoxicity toward normal cells (BV2, HUVEC, ADSC) at 100 μM, demonstrating excellent selectivity.
Metabolic reprogramming: In TS603 and HT1080 tumor cells, Flc (2.5–20 μM) significantly suppresses the production of the oncometabolite 2-HG while reducing histone H3 methylation levels.
Immune activation: In an orthotopic liver cancer model using immunocompetent C57BL/6 mice, Flc not only inhibits tumor growth but also remodels the “immune-cold” tumor into an “immune-hot” state by activating the cGAS-STING pathway, markedly increasing CD8⁺ T cell infiltration and reversing T cell exhaustion.
Synergistic combination: Flc combined with an anti-PD-1 antibody produces a synergistic anti-tumor effect, offering a new strategy to overcome immune evasion in mIDH1-mutant tumors.
Experimental Support: A Rigorous System Ensuring Research Reliability
This landmark study spanning molecular screening, cellular validation, and animal models relied on standardized experimental systems. To ensure accuracy and reproducibility in cellular functional assays, the authors employed rigorous protocols across various cell culture systems. Notably, for the culture of adipose-derived mesenchymal stem cells (ADSCs), the research team selected ExCell Bio’s OptiVitro® MSC Expansion Medium XF (ME000-N023) along with standardized procedures, providing a high-quality cellular model foundation for Flc safety evaluation and ensuring the reliability of in vitro experimental data.
With the establishment of the Ccc-Chip platform, the discovery of covalent drugs from natural products is entering a new era of high-throughput, precision screening. This study not only contributes Flc, a novel immunomodulatory molecule, to the drug development targeting mIDH1 but also provides a universal technological platform for mining active ingredients from traditional medicinal plants. In the future, as this platform is applied to more targets, it is expected to bring groundbreaking treatment options to cancer patients.
Journal: iMeta
Impact Factor: IF = 33.2
Article Link:https://doi.org/10.1002/imt2.70107
Product Used:ExCell Bio OptiVitro® MSC Expansion Medium XF (ME000-N023)
